Work

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.1063

Authors: Nagi S. El Saghir, Yoon Sim Yap, Yesim Eralp, Seock-Ah Im, Hamdy A. Azim, Julie Rihani, Nikita Volkov, Shin-Cheh Chen, Hakan Harputluoglu, Patrapim Sunpaweravong, Yuan-Ching Chang, Teresa Delgar Alfaro, Jiwen Wu, Huilin Hu, Ming Gao, Yen-Shen Lu

Institutions: American University of Beirut Medical Center, National Cancer Centre Singapore, Acıbadem University, Seoul National University, Seoul National University Hospital, Cairo University hospitals, City Clinical Oncology Center, Chang Gung University, Chang Gung Memorial Hospital, Inonu University, Prince of Songkla University, Mackay Memorial Hospital, Novartis (Switzerland), National Taiwan University Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W4379285692

Cites:

Cited by: 11

Related to: 10